About us
Built for biopharma. Designed for trust.
Why we exist
Intelligence should strengthen expertise—not replace it.
01
Specialized knowledge is difficult to find and reuse.
02
Critical workflows still depend on individual experience.
03
General-purpose AI rarely fits enterprise knowledge, tools, and workflows.
04
Critical know-how can leave when experienced people leave.
05
AI agents should belong to the organization—not individual builders.
06
Purpose-built agents scale across critical workflows.
Where science, engineering,
and governance work together.
Biotechnology
Understanding research, biological systems, and development.
AI & Machine Learning
Turning specialized knowledge into models, workflows, and Agents.
Pharma Engineering
Connecting intelligence with real production environments.
Quality & Regulatory
Designing for traceability, quality, governance, and practical adoption.
From scientific challenges
to enterprise intelligence
From scientific challenges to an enterprise AI platform built for biopharma.
2018
Founded in Taiwan
Established as the company that would later become therapiAI.
2024
therapiAI Takes Shape
Rebranded and secured seed funding led by Cherubic Ventures.
2025
CDMO Validation
Partnered with Taiwan-listed CDMOs to launch proof-of-concept projects.
2025
Agent Platform Expansion
Launched ADC and QD AI Agents across R&D, quality, and development workflows.
2018
Founded in Taiwan
Established as the company that would later become therapiAI.
2024
therapiAI Takes Shape
Rebranded and secured seed funding led by Cherubic Ventures
2025
CDMO Validation
Partnered with Taiwan-listed CDMOs to launch proof-of-concept projects.
2025
Agent Platform Expansion
Launched ADC and QD AI Agents across R&D, quality, and development workflows.
Founder & CEO
Michael Han
Education
Ph.D. Candidate, Graduate Institute of Technology, Innovation and Intellectual Property Management, NCCU
When we founded therapiAI in 2018, our goal was not to showcase AI, but to solve real problems in the pharmaceutical industry.
We chose to focus on CDMOs because they represent one of the industry’s most complex and highly regulated environments—where technology must earn trust through security, practical adoption, and measurable outcomes.
Today, we continue to build AI Agents that work alongside domain experts and fit into real pharmaceutical workflows. Our ambition is to grow from Asia into a trusted AI platform for pharmaceutical manufacturing worldwide.
What truly transforms industries is not technology, but trust.
Founders & Executive Leadership
Our leadership team unites expertise across biotechnology, AI, pharmaceutical engineering, and quality systems to shape the future of biopharma intelligence.
Alicja Lee
Co-Founder & CTO
Education
M.S. in Electrical Engineering, NTU
Experience
CTO of therapiAI; frequent speaker on core module architecture; holds dual background in engineering and linguistics.
Polly Lin
Co-Founder
Education
M.S. in Electrical Engineering, NTU
Experience
CTO of therapiAI; frequent speaker on core module architecture; holds dual background in engineering and linguistics.
Jesse Huang
COO
Education
Ph.D. in Entomology, NTU
Experience
AI executive with a background in biomedical sciences, product strategy, and business operations. Experienced in commercializing enterprise AI solutions across healthcare and finance, with a current focus on scaling Agentic AI.
Advisor
Paul Lin
Medical Advisor
Education
Ph.D., Institute of Biotechnology, NTU
M.D., School of Medicine, NDMC
Experience
Attending Orthopedic Surgeon at Tri-Service General Hospital; Medical Advisor at therapiAI, providing clinical insight and medical application strategy.